Sulfadoxine-pyrimethamine

Wiwal®
Universal Corporation
Chemoprevention
Intermittent preventative treatment (TPP-1)

Sulfadoxine-pyrimethamine

Access
-
Approved
Product vision
  • Intermittent preventive treatment during pregnancy (IPTp)
  • Intermittent preventive treatment of infants (IPTi)
Dosing
  • 3 tablets of 500 mg sulfadoxine - 25 mg pyrimethamine, to be given at the beginning of the 2nd trimester of pregnancy until delivery
Efficacy
  • WHO affirmed the effectiveness of IPTp using SP (IPTp-SP), including in areas with SP resistance
  • Full course of IPTp-SP decreases incidence of low birthweight babies by 29%, severe maternal anaemia by 38%, and neonatal mortality by 31%.
Key features
  • One of the few health interventions showing reductions in neonatal mortality
  • Adapted SP packaging to ensure correct use and to improve perception and uptake
Challenges
  • Delivery of IPTp requires a functioning antenatal care platform and access to quality-assured SP
  • Improving quality perceptions about SP and expanding access through community health worker channels can increase IPTp coverage
Status
  • WHO Prequalification in August 2022. Approved in Kenya with further registration submissions (Cameroon, & Ghana)
  • 250 mg Sulfadoxine-12.5 mg pyrimethamine dispersible tablets for use in infants (IPTi) approved by Global Fund Expert Review Panel in 2022
Next milestone
  • Ongoing country registrations in Uganda, Rwanda, Zambia, Malawi, Tanzania
Project Director
  • Pierre Hugo